Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Top Cited Papers
Open Access
- 15 January 2001
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 107 (2) , 135-142
- https://doi.org/10.1172/jci11914
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Control of apoptosis by Rel/NF-κB transcription factorsOncogene, 1999
- Aberrant rel/nfkb genes and activity in human cancerOncogene, 1999
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999
- Suppression of nitric oxide synthase and the down‐regulation of the activation of NFκB in macrophages by resveratrolBritish Journal of Pharmacology, 1999
- IEX -1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell SurvivalScience, 1998
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Cyclosporin A interferes with the inducible degradation of NF‐xB inhibitors, but not with the processing of p105/NF‐xB1 in T cellsEuropean Journal of Immunology, 1997
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993